Carbon Monoxide Monitoring and Emergency Treatment

Carbon Monoxide Poisoning Clinical Trial

— COMET  

Official title:

Randomized Trial of Carbon Monoxide Elimination Kinetics With Oxygen Delivered by Continuous Positive Airway Pressure Compared to Face Mask

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT00841165
• Other study ID #: CHRMS 09-056
• Status: Unknown status
• Phase: N/A
• First received: February 10, 2009
• Last updated: April 1, 2010
• Start date: January 2009
• Est. completion date: June 2010

Study information

• Verified date: April 2010
• Source: University of Vermont
• Contact: Tyler J Lemay, BFA
• Email: tyler.lemay[@]uvm.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Carbon monoxide (CO) has been called a "silent killer", and those patients who survive CO poisoning are at risk of neurological damage, which may be permanent. CO is a leading cause of unintentional poisoning deaths in the United States, and the odorless gas results in an estimated average of 20,636 emergency department (ED) visits each year. Oxygen is the antidote for CO poisoning, and it acts both by attenuating toxic effects and enhancing elimination. A fractional inspired concentration of oxygen (FiO2) of 0.7 to 0.9 may be achieved by administration of 100% oxygen delivered using a reservoir with a facemask that prevents rebreathing. Hyperbaric oxygen therapy may provide added benefit for patients with CO poisoning, but this therapy is unavailable in many parts of the United States including Vermont. Use of a continuous positive airway pressure (CPAP) mask may achieve an FiO2 of 1.0, but the effects of delivering an FiO2 of 1.0 compared to 0.7 in CO poisoning are unknown. CPAP, by comparison, is inexpensive, portable, and available in most EDs. In this study, the investigators are testing the hypothesis that oxygen delivered by CPAP will improve both CO washout kinetics and functional outcomes, compared to the standard therapy of oxygen delivered by non-rebreathing facemask. Specific Aim 1 will provide toxicokinetic data to support a potential benefit in the use of CPAP for CO poisoning, by comparing CO elimination kinetics in response to oxygen therapy delivered by non-rebreathing facemask versus CPAP. The 20 patients expected in our first year will provide adequate power to detect a 20% fall in half-time of CO elimination. While CPAP may increase CO washout rates, as predicted in Specific Aim 1, demonstration of real functional benefit will be tested in Specific Aim 2. This Aim seeks to determine functional (neuropsychological) outcomes in patients with CO poisoning treated with oxygen therapy delivered by non-rebreathing facemask versus CPAP. Data showing a therapeutic benefit from CPAP in CO poisoning would have clinical implications. Compared to hyperbaric oxygen therapy, CPAP therapy can begin earlier, including the pre-hospital setting, for patients with known exposure. With the frequent nature of CO poisoning and the widespread availability of CPAP, a potential benefit could lead to improved outcomes for the 20,000+ patients who present to EDs annually.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 40
• Est. completion date: June 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Elevated Carboxyhemoglobin Level (non-smokers >8%, smokers >12%)

• 18 years of age or older

• Able to provide informed consent as assessed by Attending Emergency Physician

Exclusion Criteria:

• Requires daily medication for active lung disease

• Altered mental status

• Hemodynamically unstable

• Requires transfer to ICU or hyperbaric oxygen facility

• Previous enrollment in the study

• No concurrent acute psychiatric illness

Related Conditions & MeSH terms

• Carbon Monoxide Poisoning
• Poisoning

Intervention

Device:
• Continuous Positive Airway Pressure
Full face CPAP at 5cm H2O and 100% oxygen
• Non-rebreather oxygen mask
Oxygen administered through a non-rebreather mask

Locations

Country	Name	City	State
United States	Fletcher Allen Health Care	Burlington	Vermont

Sponsors (1)

Lead Sponsor	Collaborator
University of Vermont

Country where clinical trial is conducted

United States, 

References & Publications (3)

Bruce EN, Bruce MC. A multicompartment model of carboxyhemoglobin and carboxymyoglobin responses to inhalation of carbon monoxide. J Appl Physiol (1985). 2003 Sep;95(3):1235-47. Epub 2003 May 16. — View Citation

Bruce MC, Bruce EN. Analysis of factors that influence rates of carbon monoxide uptake, distribution, and washout from blood and extravascular tissues using a multicompartment model. J Appl Physiol (1985). 2006 Apr;100(4):1171-80. Epub 2005 Dec 8. — View Citation

Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med. 2009 Mar 19;360(12):1217-25. doi: 10.1056/NEJMcp0808891. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Half life of Carboxyhemoglobin		Every 15 minutes during treatment